Bioniche Life Sciences Inc. operates in the Pharmaceutical preparations sector. Bioniche Life Sciences Inc. (Bioniche) is a biopharmaceutical company. The Company develops, manufactures and markets products for human and animal health markets worldwide. It operates in three segments: human health, animal health and food safety. Its human health business unit develops human cancer therapies, with a focus on the research and development of the Company's Mycobacterial Cell Wall-DNA Complex (MCC) technology platform for the treatment of bladder and other cancers, and its oligonucleotides, which show pre-clinical promise in the treatment of leukemia and other cancers. Its animal health business unit develops, manufactures and markets animal health biopharmaceutical products worldwide. Its food safety business unit is engaged in researching, developing, manufacturing and marketing of veterinary biopharmaceutical products. In July 2009, it had signed a licensing, development and supply agreement UrocidinTM, a formulation of MCC for the treatment of bladder cancer. In our complete report available for purchase the company is compared to: QLT Inc., Nuvo Research Incorporated and Cardiome Pharma Corp..